The unparalleled accuracy of Nexstim’s SmartFocus® nTMS technology has been validated in neurosurgical diagnostics in over 96 peer-reviewed articles, covering over 4,194 patients. There are several world leading centers, such as Charité Berlin, Mayo Clinic, MD Anderson Cancer Center etc., that rely on our SmartFocus® TMS technology: we have an installed base of 170 NBS Systems globally.
Now this same unique technology is available for treatment of major depressive disorder (MDD) and chronic neuropathic pain – indications where the company is focused on. SmartFocus® TMS technology promises improved efficacy of TMS depression treatment and it is rapidly gaining traction as treatment modality: we have several NBT® systems installed in the United States, Europe and in Asia. There are already promising results on the use of SmartFocus ® TMS in depression therapy showing higher response and remission outcomes than what is usually reported for MDD treatment with TMS.
We are well positioned to a disruptive shift in depression treatment and therapy delivery. In times when neurostimulation is rapidly gaining traction as a mainstream treatment modality, Nexstim is a unique investment opportunity.